Microbiome Drugs Articles & Analysis
24 news found
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA. On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel drug, as ...
Phase 3 ECOSPOR III Study of SER-109 Data Encore Cancer patients are at greater risk of developing rCDI and tend to have worse outcomes, due to their weakened immune system and frequent antibiotics exposure.i Encore data from the completed double-blind, randomized, placebo-controlled Phase 3 ECOSPOR III trial (NCT03183128) show that the investigational microbiome therapeutic ...
Food and Drug Administration (FDA) in mid-2022, positioning SER-109 up to potentially become the first ever FDA-approved microbiome-based therapeutic for treating recurrent C. difficile infections with a potential product launch in the first half of 2023. ...
According to published clinical data from Memorial Sloan Kettering, patients undergoing this type of transplant who have less diverse gut flora are significantly more likely than patients with a richer microbiome to experience infection or GvHD. The trial will help inform whether SER-155 can restore a healthy microbiome and support transplant recovery. About ...
Seres expects to finalize a Biologics License Application (BLA) submission for SER-109 with the U.S. Food and Drug Administration (FDA) in mid-2022. “We are eager to showcase new data that further validate the potential of our investigational microbiome therapeutic, SER-109, at the world’s largest gathering of physicians and researchers in the ...
--(BUSINESS WIRE)--May 4, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. ...
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products. Bio-Me offers a wide range of proprietary solutions to facilitate the gut ...
ByBio-Me
The Pharmabiotics Conference brings together players from academia and industry and it is an incredible opportunity to meet stakeholders and discuss the further innovation in microbiome-based drug products and regulatory affairs. Reach out to us if you want to meet during the conference event or to receive any further information about Microviable. ...
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational ...
He has been a valued leader at large companies (3M) and emerging startups (Rion, StemoniX, Rebiotix) where he made significant contributions to the pioneering development of regenerative exosome and microbiome therapeutics, 3D organoids for drug discovery, and novel drug delivery technologies. ...
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 6thMicrobiome Movement – Drug Development Summit Europe 2022 in London during January 25th-27th, 2022. The presentation has been included in stream A titled “Understanding mechanisms of action & preclinical development” the 26th at 13.45. Microbiota Adaptation ...
EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the mechanical completion of a new purpose built world-class facility at Strathclyde Business Park, Glasgow, for manufacturing and quality control of its high-diversity microbial therapeutics, and an expansion of its corporate offices to support an ...
The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development and manufacturing capabilities. ...
Isaksen will first be presenting how we support companies in their development of microbiome modulating drugs with our PMP™ technology for targeted microbiome analysis. Following that, our COO Warren Flood will do a joint presentation with Ricardo Valladares, CSO at Siolta Therapeutics showcasing how we work together to facilitate their ...
ByBio-Me
” SFA plans to expand the evaluation of one of its six microbiome-derived drugs, SFA002, in this new trial. This 30-subject open-label clinical trial in patients with mild-to-moderate psoriasis will enroll 30 subjects into two cohorts with 15 subjects each. ...
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 5th Microbiome Movement – Drug Development Summit Europe 2021 being held virtually during January 27th-29th, 2021. ...
Symberix co-founder Matthew Redinbo gave the keynote address at the AACR Microbiome, Viruses, and Cancer conference on Friday, February 21, 2020. The special conference covers the contribution of bacterial, viral, and fungal pathogens to the development of cancers, as well as the impact of the microbiome on cancer therapy. Dr. Redinbo’s keynote, titled ...
Symberix, Inc. is a biopharmaceutical company focused on developing the first generation of gut microbiome-targeting drugs to treat lower GI disorders. Gut microbes express numerous proteins, including a family of bacterial β-glucuronidase enzymes capable of generating toxic metabolites of many common medications in the lower GI tract. Symberix is developing ...
LISCure Biosciences, a biotech company that researches and develops bacteria-mediated immunotherapy, has succeeded in attracting 5 million USD of seed funding investment. NHN Investment, Shinhan Investment, and KB Securities have participated in the financing, and LISCure is expected to strengthen its research and development capabilities of key technologies with the funds. ...
Long-term objectives of the planned work include the development of a therapeutic adjunct to prevent adverse gastrointestinal events associated with essential drugs and the development of a microbiome-targeted drug to treat inflammatory bowel disease. ...